Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-50816
Lung Cancer 2010 Sep 01;693:361-4. doi: 10.1016/j.lungcan.2010.05.019.
Show Gene links Show Anatomy links

Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.

Murakami S , Yokose T , Saito H , Sakuma Y , Matsukuma S , Hasegawa C , Kondo T , Oshita F , Ito H , Tsuboi M , Nakayama H , Kameda Y , Noda K , Yamada K .


???displayArticle.abstract???
The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small-cell lung cancer. The clinicopathological features of EML4-ALK-positive adenocarcinoma are reported to include its high incidence in young, non-smoking patients, tumors that show distinct solid or acinar growth patterns with or without signet-ring cell histology, and its mutually exclusive occurrence with mutations in EGFR and KRAS. However, the clinical findings have not been well described. Here, we report a case of EML4-ALK-positive lung adenocarcinoma that showed multiple metachronous lesions on the pleura and pulmonary field, suspected to be a recurrence of lung adenocarcinoma after a 20-year disease-free interval. The slow clinical course may be characteristic of EML4-ALK-positive lung adenocarcinoma. Therefore, long-term observation of patients with EML4-ALK-positive lung adenocarcinomas is required after surgery.

???displayArticle.pubmedLink??? 20659620
???displayArticle.link??? Lung Cancer